PSNL News and Press, Personalis Inc. From 04/05/23

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time. About Personalis, Inc. At ...

Personalis’ NeXT Personal® liquid biopsy assay will be deployed in a collaboration for TRACERx to assess approaches for earlier lung cancer recurrence post-surgery and for relapse Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, Universi...

New findings reinforce potential of company’s highly-sensitive MRD offerings for earlier recurrence detection and therapy response monitoring Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for C...

Company Will Explore Use of NeXT Personal® in AstraZeneca Trial Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical c...

Personalis ( NASDAQ: PSNL ) on Thursday said the company appointed Christopher Hall as CEO and a member of the board, effective immediately. Hall will become CEO in addition to his role as president. Hall joined Personalis in October 2022 and became presiden...

New Leadership Structure Supports Strategic Objectives to Drive New Paradigm in Cancer Management and Lead in Minimal Residual Disease Testing Aaron Tachibana Promoted to COO and Dr. Richard Chen to EVP, R&D Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for ...

Personalis, Inc. (PSNL) Q4 2022 Results Conference Call February 23, 2023 05:00 PM ET Company Participants Caroline Corner - Investor Relations Aaron Tachibana - Interim Chief Financial Officer and Chief Financial Officer Chris Hall - President Rich Chen - Chief Me...

Personalis press release ( NASDAQ: PSNL ): Q4 GAAP EPS of -$0.67 misses by $0.03 . Revenue of $16.7M (-19.2% Y/Y) beats by $0.45M . Sees Q1 2023 total company revenue of approximately $17.5 million. The consensus estimate is $21.90M. Sees FY 2023 total company ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights. Recent Business Highlights Announced a continuing partnershi...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast t...